Hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib as frontline therapy for Ph-positive ALL: a propensity score analysis

BACKGROUND: The clinical efficacy of hyper-CVAD (HCVAD) + ponatinib has not been compared to that of HCVAD + dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial. METHODS: We analyzed 110 patients with newly diagnosed Ph+ A...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Sasaki, Koji, Jabbour, Elias, Ravandi, Farhad, Short, Nicholas J., Thomas, Deborah, Garcia-Manero, Guillermo, Daver, Naval, Kadia, Tapan, Konopleva, Marina, Jain, Nitin, Issa, Ghayas C., Jeanis, Vicki, Moore, Gal, Garris, Rebecca, Pemmaraju, Naveen, Cortes, Jorge E., O'Brien, Susan, Kantarjian, Hagop
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321539/
https://ncbi.nlm.nih.gov/pubmed/27479888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30231
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky